














Copyright©2020 by Faculty of Medicine Diponegoro University and Indonesian Society of Human Genetics 
 
Case Report 
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Abstract 
Background: Primary sclerosing cholangitis (PSC) is a rare chronic immune-
mediated liver disease affecting intra and extrahepatic bile ducts, in which 
inflammation and fibrosis are the main factors that lead to biliary stricture. The 
pathogenesis of this disease is still unclear. It happens approximately 0.5 to 1.3 cases 
per 100,000 person-years in Northern Europe. PSC is difficult to diagnose until 
complications arise. PSC can also be a manifestation of mixed connective tissue 
disease (MCTD) in the liver. A chronic immune disease that has occurred since 
childhood may result in delayed development and short stature.  
Case Presentation:   A 18-year-old female presented with icteric, anemia, short 
stature, and absence of menstruation. Laboratory and radiological findings suggested 
obstruction of intra and extrahepatic biliary duct (conjugated bilirubin 11,80 mg/dL), 
severe anemia, normal sex hormone levels, increased RNP/SM antibodies. 
Histopathology showed liver cirrhosis suggestive for primary sclerosing cholangitis. 
The patient then was given biliary stenting, transfusion of packed red cell, 
immunosuppresive, corticosteroid, ursodeoxycholic acid. Within a year of treatment, 
there was a significant decrease of direct bilirubin and improvement in symptoms. 
Conclusion: Patient with PSC, MCTD, and short stature is a very rare case. This is the 
first case that has been found in dr. Kariadi Hospital, Semarang. It has high mortality 
rate and difficult to diagnose and treat. According to multiple guidelines, this patient 
should have liver transplantation, but in this case, biliary stenting and oral treatments 
have resulted in an excellent outcome. 
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INTRODUCTION 
Primary sclerosing cholangitis (PSC) is a chronic, 
progressive, stricturing disease of the biliary tree. Most 
patients with primary sclerosing cholangitis have no 
symptoms. This disease is usually detected based on 
abnormal result of biochemical tests of liver function on 
routine blood testing.  
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Patients may remain asymptomatic for many years 
despite the presence of the advanced disease. When 
symptoms develop, it will result in obstruction to bile 
flow, including jaundice,itching, right upper quadrant 
abdominal pain, fever, and chills. Symptoms may also 
include weight loss and fatigue. The development of 
symptoms usually suggests the presence of advanced 
diseases including liver cirrhosis, portal hypertension, 
and end-stage liver disease. (1) PSC is strongly 
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appears to be much less common in Southeast Asia. It is 
most common in Northern European countries and 
North America, where the reported incidence and 
prevalence range from approximately 0.5 to 1.3 cases 
per 100,000 person-years and 3.85 to 16.2 cases per 
100,000 person-years, respectively. (3) Most patients 
with primary sclerosing cholangitis are men (75%) with 
an average age of approximately 40 years at diagnosis. 
Connective tissue diseases (CTDs) are generally 
referred to as a group of systemic disorders with 
abnormalities in the tissues containing collagen and 
elastin. Usually, CTDs are characterized by overactivity 
of the immune system from unknown causes resulting 
in the production of autoantibodies.(4) Further, the liver 
is frequently involved in connective tissue diseases 
(CTD), most commonly in the form of liver function test 
biochemical changes with predominant cholestatic or 
hepatocellular patterns.(5) The purpose of this report is 
to present a rare case of primary sclerosing cholangitis 
that overlap with mixed connective tissue disease 
(MCTD) and delayed development that has occurred 
since childhood.  
 
CASE REPORT 
 A 18-year-old female presented with yellow 
discoloration of eyes and body that she had had for the 
past 4 years. The discoloration started from the eyes then 
developed throughout her whole body. She also 
complained of generalized pruritus, weakness, and right 
upper quadrant discomfort. The abdominal discomfort 
was intermittent and not referred to other areas. She also 
had dark urine and acholic stools. The patient also did 
not have her period and there was no secondary sexual 
characteristic development. There were no fever, 
diarrhea, cough, night sweats, changes in mental status, 
signs of any encephalopathy. She had a history of anemia 
with repeated blood transfusions. 
Physical examination revealed stable hemodynamic, 
height 142 cm (short stature), body mass index 13.8 
(underweight), icteric sclera and body with scratch mark 
throughout the body, breast and pubic hair were not 
developed, liver was not palpable with liver span 7 cm 
and splenomegaly (Schuffner 2). There were no ascites, 
spider naevi, palmar erythema, and white nail. On 
admission, the laboratory data showed anemia 
(hemoglobin 7.6 mmol/L, MCV 28,8 fl, MCH 28.8 pg, 
FT4 18,35 pmol/L, TSHS 2,39 IU/mL , aspartate 
aminotransferase 34 IU/l, alanine aminotransferase 18 
IU/l, alkaline phosphatase 796 IU/l, γ-glutamyl 
transpeptidase 242 IU/l, total bilirubin 16,1 mg/dL, and 
direct bilirubin 14,3 mg/dL. The viral hepatitis B and C 
marker was negative. ANA and Anti dsDNA tests were 
negative. Increased levels of DFS70 and RNP/Sm 
antibodies from the ANA profile can be concluded as 
MCTD. The hormone levels of FSH, prolactin, and 
estradiol were normal. USG showed hypoplasia of the 
uterus (3.27 x 2.27 x 1.17 cm). MRCP showed a 
sclerosing cholangitis appearance. The patient had 
ERCP and 10 Fr 7 cm biliary stenting. 
 Liver biopsy showed hepatic cirrhosis with 
cholestasis that was suggestive for primary sclerosing 
cholangitis. Treatment of cyclosporine (25mg/day), 
methylprednisolone (32,5mg/day) for four days and then 
tapering off to 4mg/day, and ursodeoxycholic acid 
(UDCA) 250mg/12 hour, packed red cell transfusion 
was given. A month later, the patient’s symptoms and 
laboratory results improved. Seven months after 
admission, the patient had melena and severe anemia 
with hemoglobin 6,7 gr%, MCV 27 fl, MCH 27 Pg, 
reticulocyte 4,79%. She was then given a packed red cell 
transfusion and Esophagogastroduodenoscopy was 
performed with Grade II esophageal varices as the result. 
 
 
Figure 1. The cholestatic pattern in primary sclerosing cholangitis (A); 




Figure 2. 1-2 Hepatocyte with the oval nucleus, smooth chromatin, 
trabecular pattern in pseudolobulus, half of the cytoplasm contains bile 
pigment, and inflammatory cells PMN, lymphocyte. No signs of 
malignancy and from trichrome stain: Fibrosis (F4). 
 
 Once a month the patient was routinely checked and 
continued her oral medication of cyclosporine 
(25mg/day), methylprednisolone 4mg/day, and 
ursodeoxycholic acid (UDCA) 250mg/12 hour 
throughout the year. Her symptoms and laboratory result 
gradually improved. Approximately a year after the 
patient had biliary stenting and oral medicine treatment, 
the yellow discoloration of the body decreased and her 
direct bilirubin level decreased to 2.21 mg/dl with a total 
bilirubin 3.26 mg/dl and severe anemia became moderate 
anemia (hemoglobin 8g%). 
 
DISCUSSION 
 We present a patient with primary sclerosing 
cholangitis (PSC) that has occurred since childhood, a 
relatively infrequent but increasingly diagnosed disease. 
PSC is characterized by chronic cholestasis, associated 
with chronic inflammation of the biliary epithelium, 
resulting in multi-focal bile duct strictures that can affect 
the entire biliary tree. Chronic inflammation leads to 
fibrosis involving the hepatic parenchyma and biliary 
tree, which can lead to cirrhosis and malignancy. The 
etiology of PSC is not fully understood.(6) PSC is strongly 
associated with inflammatory bowel disease. Like many 
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other autoimmune conditions such as connective tissue 
disease. Clinical manifestations are broad, and the 
spectrum encompasses asymptomatic cholestasis, icteric 
cholangitis with pruritus, cirrhosis, and 
cholangiocarcinoma.. On clinical exam, patients may be 
unremarkable or present with jaundice and pruritus that 
can range from mild to disabling, resulting in severe 
excoriations and a decreased quality of life.  The 
diagnosis of PSC is based on elevated serum markers of 
cholestasis (AP, γGT, Bilirubin) and imaging findings – 
magnetic resonance cholangiopancreatography 
(MRCP), endoscopic retrograde 
cholangiopancreatography (ERCP) demonstrating 
characteristic changes of bile duct with multifocal 
strictures and segmental dilatations when all other 
possible cholestatic disorders and secondary causes are 
excluded. On biopsy, PSC presents with fibrous 
obliteration of small bile ducts, with concentric 
replacement by connective tissue in an “onion skin” 
pattern. (7) The ppatient repeatedly had anemia and 
received packed red cell transfusion and 
Ursodeoxycholic acid (UDCA) for cholestasis as a 
hydrophilic bile acid, and it has been the most 
extensively studied putative pharmacological treatment 
for PSC.(8) Immunosuppressive agent and corticosteroid 
were given to this patient because of the autoimmune 
etiology of the disease. Biliary stenting was performed 
in this patient to help the stream of the bile.(9) 
 Even though studies show that UDCA therapy 
improve biochemical parameters but the overall 
beneficial effects for patients with PSC, in particular, 
survival benefit, are still uncertain. Immunosuppression 
in PSC is controversial and the majority of centers and 
publications do not recommend a routine administration 
of corticosteroids and other immunosuppressants.(10) In 
this patient, it was objectively proved that UDCA, 
immunosuppressant, corticosteroid combined with 
biliary stenting improved symptoms and laboratory 
results with marked decreased of direct bilirubin and 
sufficient hemoglobin levels. Her cholestatic pattern can 
be measured objectively through her laboratory 
examination. The first direct bilirubin level was 14,3 
mg/dL before biliary stenting and oral treatment and 
approximately a year after the treatment, her direct 
bilirubin level markedly decreased to nearly normal 
level and her hemoglobin level was increased to nearly 
normal level. Treatment modality for PSC is still 
challenging with liver transplantation as the definitive 
treatment, where the survival rate may increase to 
90%.(11) However, when liver transplantation is not an 
option, we can consider giving biliary stenting, 
immunosuppressant, corticosteroid, UDCA as 
supporting therapy. Even though the mean duration of 
the stent  patency is about 12 months and needs close and 
regular monitoring and prolonged corticosteroid therapy 
may give serious side effects, they are still considered an 
effective treatment modality for this patient that does not 
have resources for liver transplantation.(12) 
 Her quality of life was improved but the patient still 
had no menstruation and her secondary sexual sign did 
not develop. Fibrotic autoimmune diseases are 
characterized by an inflammatory process, which 
induces and sustains robust fibrosis. Among the various 
fibrogenic factors in autoimmune diseases, interleukin-1 
(IL-1), IL-6, and TGF-β have a relevant role.(13) Short 
stature may be either a variant of normal growth or 
caused by a disease. Almost any serious disease can 
cause growth failure. The abnormalities of growth and 
maturation that occur in children with acute or chronic 
illnesses may result from the primary disease process 
because of increased energy needs or nutritional 
deprivation (eg, decreased intake or malabsorption). The 
growth failure is closely related to the inflammatory 
disease process (mediated by proinflammatory 
cytokines), as well as decreased food intake, 
malabsorption, and/or high-dose glucocorticoids if used 
for treatment.(14) Further examination should be done to 
establish the cause of her short stature and undeveloped 




 PSC is a rare cholestatic disease with unclear 
etiology. Liver involvement in MCTD patients is also 
rare. Chronic diseases can also decrease body height 
through their effects on overall health. Even though there 
is no definitive proof that stenting and oral treatment give 
improvement in PSC patients, but in this case, it is 
objectively proved that they diminished cholestatic 
pattern of this patient. However, liver transplantation is 
still a definitive therapy for PSC patient. Further studies 
are needed for better understanding of the disease and for 
development of an optimal therapeutic strategy for 
patients with PSC. 
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